With the inclusion of KRAS hotspot mutation screening together with Uromonitor®, this preliminary data presents this noninvasive approach as a true alternative to cystoscopy for NMIBC follow-up or even as a population screening and/or initial diagnosis for bladder cancer. This evidence concerns the gene KRAS and urinary bladder cancer.